• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[具体微生物名称]的定植可减缓慢性肾脏病(CKD)的进展,并减少CKD患者的心脏重塑。 (注:原文中“Colonization with”后面缺少具体的微生物名称)

Colonization with slows the progression of CKD and reduces cardiac remodeling in CKD.

作者信息

Xiong Xiaozhong, Ho Melody, Jaber Karim, Mishra Rashmi, Charytan Amalya, Zaidan Nadim, Schlamp Florencia, Fishman Glenn I, Nazzal Lama

机构信息

Division of Nephrology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.

Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.

出版信息

bioRxiv. 2025 May 14:2025.05.14.654014. doi: 10.1101/2025.05.14.654014.

DOI:10.1101/2025.05.14.654014
PMID:40462893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12132296/
Abstract

Accumulation of oxalate in patients with chronic kidney disease (CKD) is associated with CKD progression and increased risk of cardiac death. Whether reducing plasma or urine oxalate slows CKD progression and prevents cardiovascular complications remains unexplored. We colonized the intestines of control and CKD mice with (), an oxalate-degrading microorganism. The mice were fed with the oxalate precursor hydroxyproline for 23 weeks at which time we assessed pathological changes in the kidney and heart. We demonstrate that reduces plasma oxalate (pOx) and creatinine levels, mitigates inflammation and fibrosis in the kidney, and reduces pathologic cardiac remodeling in the hearts of CKD mice. RNA-seq analysis of ventricular tissue of CKD mice reveals dysregulated expression of metabolic pathways while colonization reverses these changes. These findings demonstrate that oxalate accumulation plays a role not only in CKD progression but also in associated cardiovascular complications and suggest that strategies to reduce plasma oxalate levels may have therapeutic benefit.

摘要

慢性肾脏病(CKD)患者体内草酸盐的蓄积与CKD进展及心脏死亡风险增加相关。降低血浆或尿液草酸盐是否能减缓CKD进展并预防心血管并发症仍未得到探索。我们用一种草酸盐降解微生物()定殖于对照小鼠和CKD小鼠的肠道。给小鼠喂食草酸盐前体羟脯氨酸23周,此时我们评估肾脏和心脏的病理变化。我们证明,()可降低血浆草酸盐(pOx)和肌酐水平,减轻肾脏炎症和纤维化,并减少CKD小鼠心脏的病理性心脏重塑。对CKD小鼠心室组织的RNA测序分析揭示代谢途径的表达失调,而定殖()可逆转这些变化。这些发现表明,草酸盐蓄积不仅在CKD进展中起作用,还在相关心血管并发症中起作用,并提示降低血浆草酸盐水平的策略可能具有治疗益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bed6/12132296/6fdb5b321294/nihpp-2025.05.14.654014v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bed6/12132296/c9c25871256c/nihpp-2025.05.14.654014v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bed6/12132296/6fdb5b321294/nihpp-2025.05.14.654014v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bed6/12132296/c9c25871256c/nihpp-2025.05.14.654014v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bed6/12132296/6fdb5b321294/nihpp-2025.05.14.654014v1-f0002.jpg

相似文献

1
Colonization with slows the progression of CKD and reduces cardiac remodeling in CKD.[具体微生物名称]的定植可减缓慢性肾脏病(CKD)的进展,并减少CKD患者的心脏重塑。 (注:原文中“Colonization with”后面缺少具体的微生物名称)
bioRxiv. 2025 May 14:2025.05.14.654014. doi: 10.1101/2025.05.14.654014.
2
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1(GLP-1)受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
3
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂用于患有早期(1至3期)非糖尿病慢性肾病的成人。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007751. doi: 10.1002/14651858.CD007751.pub2.
4
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
5
Interventions for chronic kidney disease in people with sickle cell disease.镰状细胞病患者慢性肾脏病的干预措施。
Cochrane Database Syst Rev. 2023 Aug 4;8(8):CD012380. doi: 10.1002/14651858.CD012380.pub3.
6
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在患有早期(1 至 3 期)非糖尿病慢性肾脏病的成人中的应用。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
7
Blood pressure targets for hypertension in people with chronic renal disease.高血压合并慢性肾脏病患者的血压目标。
Cochrane Database Syst Rev. 2024 Oct 15;10(10):CD008564. doi: 10.1002/14651858.CD008564.pub3.
8
Antioxidants for chronic kidney disease.用于慢性肾病的抗氧化剂。
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD008176. doi: 10.1002/14651858.CD008176.pub2.
9
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.慢性肾脏病患者的合生菌、益生元和益生菌。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013631. doi: 10.1002/14651858.CD013631.pub2.
10
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.用于治疗糖尿病和慢性肾脏病患者的胰岛素及降糖药物。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2.

本文引用的文献

1
Comparison of Plasma Oxalate Measurement Methods in Patients With End-Stage Kidney Disease.终末期肾病患者血浆草酸盐测量方法的比较
Kidney Int Rep. 2025 Mar 30;10(6):2045-2048. doi: 10.1016/j.ekir.2025.03.053. eCollection 2025 Jun.
2
Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis.抑制肝草酸过度生成可改善代谢功能障碍相关脂肪性肝炎。
Nat Metab. 2024 Oct;6(10):1939-1962. doi: 10.1038/s42255-024-01134-4. Epub 2024 Sep 27.
3
The Kidney-Gut Axis as a Novel Target for Nutritional Intervention to Counteract Chronic Kidney Disease Progression.
肾-肠轴作为营养干预以对抗慢性肾脏病进展的新靶点。
Metabolites. 2024 Jan 22;14(1):78. doi: 10.3390/metabo14010078.
4
Gut-immune axis and cardiovascular risk in chronic kidney disease.慢性肾脏病中的肠道-免疫轴与心血管风险
Clin Kidney J. 2023 Dec 13;17(1):sfad303. doi: 10.1093/ckj/sfad303. eCollection 2024 Jan.
5
Major urinary protein () gene family deletion drives sex-specific alterations in the house-mouse gut microbiota.主要尿蛋白()基因家族缺失导致实验鼠肠道微生物群的性别特异性改变。
Microbiol Spectr. 2024 Feb 6;12(2):e0356623. doi: 10.1128/spectrum.03566-23. Epub 2024 Jan 3.
6
Status of Mitochondrial Oxidative Phosphorylation during the Development of Heart Failure.心力衰竭发展过程中线粒体氧化磷酸化的状态
Antioxidants (Basel). 2023 Oct 31;12(11):1941. doi: 10.3390/antiox12111941.
7
CISH impairs lysosomal function in activated T cells resulting in mitochondrial DNA release and inflammaging.CISH 损害活化 T 细胞中的溶酶体功能,导致线粒体 DNA 释放和炎症老化。
Nat Aging. 2023 May;3(5):600-616. doi: 10.1038/s43587-023-00399-w. Epub 2023 Apr 17.
8
The major urinary protein gene cluster knockout mouse as a novel model for translational metabolism research.主要尿蛋白基因簇敲除小鼠作为转化代谢研究的新型模型。
Sci Rep. 2022 Aug 1;12(1):13161. doi: 10.1038/s41598-022-17195-y.
9
The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation.肠道微生物群(微生物组)与心血管疾病及其治疗调节。
Front Cell Infect Microbiol. 2022 Jun 20;12:903570. doi: 10.3389/fcimb.2022.903570. eCollection 2022.
10
Cardiac metabolic remodelling in chronic kidney disease.慢性肾脏病中的心脏代谢重塑
Nat Rev Nephrol. 2022 Aug;18(8):524-537. doi: 10.1038/s41581-022-00576-x. Epub 2022 May 30.